VTX002 for Colitis, Ulcerative
Phase-Based Progress Estimates
Effectiveness
Safety
Colitis, Ulcerative+2 More
VTX002 - DrugEligibility
18+
All Sexes
What conditions do you have?
Select
Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
This trial is testing a new drug to see if it's safe and effective in treating moderate to severe ulcerative colitis. Up to 180 participants will be given the new drug daily for 28 days to 13 weeks, and then followed for up to 36 months.
Eligible Conditions
- Colitis, Ulcerative
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 4 Secondary · Reporting Duration: Day 1 of Induction Treatment Period to week 13
Week 13
Endoscopic improvement at Week 13
Histologic remission at Week 13
Mucosal Healing at Week 13
Symptomatic remission at Week 13
Week 13
Clinical remission at 13 weeks
Trial Safety
Safety Progress
This is further along than 68% of similar trials
Trial Design
3 Treatment Groups
VTX002 Dose A
1 of 3
VTX002 Dose B
1 of 3
Placebo
1 of 3
Experimental Treatment
Non-Treatment Group
180 Total Participants · 3 Treatment Groups
Primary Treatment: VTX002 · Has Placebo Group · Phase 2
VTX002 Dose A
Drug
Experimental Group · 1 Intervention: VTX002 · Intervention Types: DrugVTX002 Dose B
Drug
Experimental Group · 1 Intervention: VTX002 · Intervention Types: DrugPlacebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: DrugTrial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: day 1 of induction treatment period to week 13
Who is running the clinical trial?
Oppilan Pharma LtdLead Sponsor
1 Previous Clinical Trials
12 Total Patients Enrolled
Snehal U Naik, PhDStudy DirectorVentyx Biosciences, Inc
Eligibility Criteria
Age 18+ · All Participants · 2 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:A person who has active UC is confirmed by endoscopy
Someone who has UC for more than three months is automatically screened for the study.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Popular Clinical Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments